Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Highly effective preservation solutions ensuring the safety and protection of personal care products
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Subscribe To Our Newsletter & Stay Updated
